Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Launched by STANFORD UNIVERSITY · Sep 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment combination for patients with a specific type of cancer called Epstein-Barr Virus (EBV) associated nasopharyngeal carcinoma (NPC). The researchers want to see how safe and effective the combination of three drugs—Gemcitabine, Docetaxel, and Toripalimab—can be for people with advanced stages of this cancer. The trial is currently looking for participants who are at least 18 years old and have not received any prior treatment for their NPC. To qualify, participants must have a good overall health status and meet specific blood and organ function requirements.

If you or someone you know is interested in participating, you can expect to receive this treatment under careful medical supervision. The trial will involve regular check-ups and tests to monitor your health throughout the study. It’s important for potential participants to understand that women who can become pregnant and sexually active men must use effective birth control during the study and for a short time afterward. This trial aims to find better ways to treat NPC, and your participation could help in advancing cancer research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Eligible disease(s) / stage(s): Locoregionally advanced EBV positive NPC (T3-4, any N OR any T, N1-3. No M1) per AJCC v 8
• • 2. Prior therapy: None for NPC permitted
• • 3. Life expectancy: 3 months at least
• • 4. Contraception requirements: Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control during treatment with toripalimab and for 4 months after the last dose.
• • 5. ECOG Performance Status of 0,1, or 2
• • 6. Age: At least 18 years old.
• CBC/differential obtained within 21 days prior to day 1 of treatment, with adequate bone marrow function defined as follows:
• • 7. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
• • 8. Platelets ≥ 100,000 cells/mm3;
• • 9. Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.);
• Adequate hepatic function within 21 days prior to day 1 of treatment, defined as follows:
• • 10. Total bilirubin ≤ 1.5 x institutional ULN;
• • 11. AST and ALT ≤ 1.5 x institutional ULN;
• Adequate renal function within 21 days prior to day 1 of treatment, defined as follows:
• • 12. Serum creatinine ≤ 1.5 mg/dl or calculated or measured creatinine clearance (CC) ≥ 50 ml/min
• • 13. Negative serum pregnancy test within 14 days prior to day 1 of treatment for women of childbearing potential
• • 14. Ability to understand and the willingness to personally sign the written IRB approved informed consent document.
• Exclusion Criteria:
• • 1. Prior systemic anticancer treatment for NPC
• • 2. Prior radiation to head and neck region or regions necessitating overlapping fields
• • 3. Concurrent use of any anti- cancer treatment, standard, alternative or investigational.
• • 4. History of allergic reactions to any agents in this study
• • 5. Autoimmune disease or organ transplant which in the judgment of the PI would increase the risk of immune checkpoint inhibition.
• • 6. Pregnant or breastfeeding
• 7. Severe, active co-morbidity, defined as follows:
• • Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy;
• • Unstable angina and/or uncontrolled congestive heart failure within past 6 months;
• • Myocardial infarction within the last 6 months;
• • Current acute bacterial or fungal infection requiring intravenous antibiotics; note that patients receiving IV antibiotics or currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible.
• • Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to day 1 of treatment;
• • 8. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive
• • 9. Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss that is tumor-related is allowed
• • 10. ≥ grade 2 peripheral sensory neuropathy